Vulvodynia is a chronic pain syndrome that affects the vulvar area and occurs without an identifiable cause. Symptoms typically include a feeling of burning or irritation. For the diagnosis to be made symptoms must last at least 3 months.
The exact cause is unknown but is believed to involve a number of factors, including genetics, immunology, and possibly diet. Diagnosis is by ruling out other possible causes. This may or may not include a biopsy of the area.
Treatment may involve a number of different measures; however, none is universally effective, and the evidence to support their effectiveness is often poor. Some of these measures include improved vulvar care, dietary changes, medications, counselling, and, if conservative treatment is not effective, surgery. It is estimated to affect up to 16% of women.
Signs and symptomsEdit
Pain is the most notable symptom of vulvodynia, and can be characterized as a burning, stinging, irritation or sharp pain that occurs in the vulva and entrance to the vagina. It may be constant, intermittent or happen only when the vulva is touched, but vulvodynia is usually defined as lasting for years.
Symptoms may occur in one place or the entire vulvar area. It can occur during or after sexual activity, when tampons are inserted, or when prolonged pressure is applied to the vulva, such as during sitting, bike riding, or horseback riding. Some cases of vulvodynia are idiopathic where no particular cause can be determined.
Vulvar vestibulitis syndrome (VVS), vestibulodynia, or simply vulvar vestibulitis or "localized (to the vestibule) provoked vulvodynia" refers to pain localized to the vestibular region. It tends to be associated with a highly localized "burning" or "cutting" type of pain. The pain of vulvodynia may extend into the clitoris; this is referred to as clitorodynia.
Vulvar vestibulitis syndrome is the most common subtype of vulvodynia that affects premenopausal women – the syndrome has been cited as affecting about 10%–15% of women seeking gynecological care.
A wide variety of possible causes and treatments for vulvodynia are currently being explored. Moreover, there are probably several causes of vulvodynia, and some may be individual to the patient.
Possible causes include Sjogren's syndrome, the symptoms of which include chronic vaginal dryness. Others include genetic predisposition to inflammation, allergy or other sensitivity (for example: oxalates in the urine), an autoimmune disorder similar to lupus erythematosus or to eczema or to lichen sclerosus, infection (e.g., yeast infections, bacterial vaginosis, HPV, HSV), injury, and neuropathy—including an increased number of nerve endings in the vaginal area. Some cases seem to be negative outcomes of genital surgery, such as a labioplasty. Initiation of hormonal contraceptives that contain low- dose estrogen before the age of 16 could predispose women to vulvar vestibulitis syndrome. A significantly lower pain threshold, especially in the posterior vestibulum, has also been associated with the use of hormonal contraceptives in women without vulvar vestibulitis syndrome. Pelvic floor dysfunction may be the underlying cause of some women's pain.
The condition is one of exclusion and other vulvovaginal problems should be ruled out. The diagnosis is based on the typical complaints of the patient, essentially normal physical findings, and the absence of identifiable causes per the differential diagnosis. Cotton swab testing is used to differentiate between generalized and localized pain and delineate the areas of pain and categorize their severity. Patients often will describe the touch of a cotton ball as extremely painful, like the scraping of a knife. A diagram of pain locations may be helpful in assessing the pain over time. The vagina should be examined, and tests, including wet mount, vaginal pH, fungal culture, and Gram stain, should be performed as indicated. Fungal culture may identify resistant strains.
Many sufferers will see several doctors before a correct diagnosis is made. Many gynecologists are not familiar with this family of conditions, but awareness has spread with time. Sufferers are also often hesitant to seek treatment for chronic vulvar pain, especially since many women begin experiencing symptoms around the same time they become sexually active. Moreover, the absence of any visible symptoms means that before being successfully diagnosed many patients are told that the pain is "in their head".
There are a number of possible treatments with none being uniformly effective. Treatments include:
A number of lifestyle changes are often recommended such as using cotton underwear, not using substances that may irritate the area, and using lubricant during sex. The use of alternative medicine has not been sufficiently studied to make recommendations.
- Education and accurate information about Vestibulodynia: Gynaecologist-led educational seminars delivered in a group format have a significant positive impact on psychological symptoms and sexual functioning in women who suffer from Provoked (caused by a stimulus such as touch or sexual activity) Vestibulodynia.
- Biofeedback, physical therapy and relaxation: Biofeedback, often done by physical therapists, involves inserting a vaginal sensor to get a sense of the strength of the muscles and help a patient get greater control of her muscles to feel the difference between contraction and relaxation. Sessions are linked with at-home recommendations including often Kegel exercises (e.g., hold for 9 seconds, relax for 30 for 10–15 sets) and relaxation.
A number of medications have been used to treat vulvodynia. Evidence to support their use, however, is often poor. These include creams and ointments containing lidocaine, estrogen or tricyclic antidepressants. Antidepressants and anticonvulsants in pill form are sometimes tried but have been poorly studied. Injectable medications included steroids and botulinum toxin have been tried with limited success.
Vestibulectomy, during which the nerve fibers to the area are cut out, may be recommended if other treatments have not been found to be effective. There have been no high quality studies looking at surgery as a treatment. While improvement has been noted in 60% to 90%, those who were treated without surgery improved in 40 to 80% of cases.
The percentage of women affected is not entirely clear, but estimates range as high as 16%. Many other conditions that are not truly vulvodynia (diagnosis is made by ruling out other causes of vulvar pain) could be confused with it. Vulvar pain is a quite frequent complaint in women's health clinics. Vulvodynia is not a new term in the medical literature.
There is an increasing tendency of women who have observed chronic vulvar pain once in a lifetime. If the pain is persistent for more than three months and has no apparent cause, it is called vulvodynia. It is estimated that 16% of women in the U.S. will have Vulvodynia at some point in their lives. According to the National Center for Biotechnology Information, U.S. National Library of Medicine, 17.9% of women reported symptoms suggestive of past Vulvodynia in 2013. Based on an analysis, 101,007 women in the 4-county area are estimated to have vulvar pain consistent with Vulvodynia, with another 218,219 having a history of such pain that has since resolved. As a result of these factors, the demand for the drugs is constantly rising. The drug type and its use is measured by the level of pain that is caused of vulvodynia. Although it is a chronic disease, at times even the minutest of pain can cause depression and anxiety among women.
Anticonvulsant is a type of medication that is used for controlling seizures or stop an ongoing series of seizures (convulsions). In Vulvodynia treatment, anticonvulsant is the most prescribed drug. Gabapentin is most reliable anticonvulsant drug available in vulvodynia treatment. Gabapentin is a drug which has long been recognized in chronic pain management as an effective way of curing pain. It contains tablets taken by mouth and works well for pain related to the nerve. The tablets are prescribed for a number of conditions impacting the central nervous system and they influence pain at the level of the spinal cord. Pregabalin is another anticonvulsant drug. It is very similar to gabapentin; however, it is reported to have fewer side effects and is possibly more operative.
- Feldhaus-Dahir, M (2011). "The causes and prevalence of vestibulodynia: A vulvar pain disorder". Urologic nursing. 31 (1): 51–4. PMID 21542444.
- Stockdale, C. K.; Lawson, H. W. (2014). "2013 Vulvodynia Guideline update". Journal of Lower Genital Tract Disease. 18 (2): 93–100. doi:10.1097/LGT.0000000000000021. PMID 24633161.
- Bornstein J, Goldstein AT, Stockdale CK, Bergeron S, Pukall C, Zolnoun D, Coady D; consensus vulvar pain terminology committee of the International Society for the Study of Vulvovaginal Disease (ISSVD). 2015 ISSVD, ISSWSH, and IPPS Consensus Terminology and Classification of Persistent Vulvar Pain and Vulvodynia. J Sex Med. 2016 Apr;13(4):607-12. doi: 10.1016/j.jsxm.2016.02.167
- National Research Center for Women and Families (October 2007). "Vulvodynia and Genital Pain". Archived from the original on 25 July 2011. Retrieved 27 August 2009.
- Moyal-Barracco, M; Lynch, P. J. (2004). "2003 ISSVD terminology and classification of vulvodynia: A historical perspective". The Journal of reproductive medicine. 49 (10): 772–7. PMID 15568398.
- Bergeron, Sophie; Binik, Yitzchak M.; Khalifé, Samir; Meana, Marta; Berkley, Karen J.; Pagidas, Kelly (1997). "The treatment of vulvar vestibulitis syndrome: Towards a multimodal approach". Sexual and Marital Therapy. 12 (4): 305. doi:10.1080/02674659708408174.
- Bergeron, Sophie; Binik, Yitzchak M.; Khalifé, Samir; Pagidas, Kelly (1997). "Vulvar Vestibulitis Syndrome: A Critical Review". The Clinical Journal of Pain. 13 (1): 27–42. doi:10.1097/00002508-199703000-00006. PMID 9084950.
- Gerber, Stefan; Bongiovanni, Ann Marie; Ledger, William J.; Witkin, Steven S. (2003). "Interleukin-1β gene polymorphism in women with vulvar vestibulitis syndrome". European Journal of Obstetrics & Gynecology and Reproductive Biology. 107: 74. doi:10.1016/S0301-2115(02)00276-2.
- Basson, Rosemary; Weijmar Schultz, Willibrord (2007). "Sexual sequelae of general medical disorders". The Lancet. 369 (9559): 409. doi:10.1016/S0140-6736(07)60197-4.
- Kellogg-Spadt, S (October 2003). "Differential Diagnosis of Pelvic Floor Dysfunction and Vulvar Pain". Retrieved 2012-09-11.
- Haefner, H. K.; Collins, M. E.; Davis, G. D.; Edwards, L; Foster, D. C.; Hartmann, E. D.; Kaufman, R. H.; Lynch, P. J.; Margesson, L. J.; Moyal-Barracco, M; Piper, C. K.; Reed, B. D.; Stewart, E. G.; Wilkinson, E. J. (2005). "The vulvodynia guideline". Journal of lower genital tract disease. 9 (1): 40–51. doi:10.1097/00128360-200501000-00009. PMID 15870521.
- Brotto, L. A.; Sadownik, L; Thomson, S (2010). "Impact of educational seminars on women with provoked vestibulodynia". Journal of Obstetrics and Gynaecology Canada. 32 (2): 132–8. PMID 20181314.
- "Vulvodynia Treatment Market by 2028". Future Market Insights. 2018-03-23.